FAGR Fagron SA

Disclosure of notifications received from Active Ownership Corporation S.à r.l. and from AOC Pharma S.à r.l.

Disclosure of notifications received from Active Ownership Corporation S.à r.l. and from AOC Pharma S.à r.l.

Regulated information

Nazareth (Belgium)/Rotterdam (The Netherlands), 19 December 2022 – 7:30AM CET

Disclosure of notifications received from Active Ownership Corporation S.à r.l. and from AOC Pharma S.à r.l.

Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received notifications from Active Ownership Corporation S.à r.l. and AOC Pharma S.à r.l.

Notification Active Ownership Corporation S.à r.l.

  • On 15 December 2022, Fagron received a notification that the shareholding of Active Ownership Corporation S.à r.l. crossed the disclosure threshold of 3% on 12 December 2022 as the result of the disposal of voting securities or voting rights and the downward crossing of the lowest disclosure threshold.
  • The notification is made by a ‘parent undertaking or a controlling person’.
  • On 12 December 2022, Active Ownership Corporation S.à r.l. held a total of 0 voting rights.
  • Based on the denominator of 72,992,654 (total number of voting rights), Active Ownership Corporation S.à r.l. held 0% of the total number of voting rights on 12 December 2022.
  • Active Ownership Corporation S.à r.l. is jointly controlled by two shareholders, Active Ownership Advisors GmbH and Active Ownership Investments Ltd. Active Ownership Advisors GmbH is controlled by Florian Schuhbauer. Active Ownership Investments Ltd. is controlled by Active Ownership LP, which is controlled by Active Ownership Management Ltd, which is controlled by Klaus Röhrig.
  • On 1 October 2019, an agreement was concluded by Active Ownership Fund SICAV-FIS SCS regarding the appointment of Active Ownership Corporation S.à r.l. as AIFM (alternative investment fund manager) for Active Ownership Fund SICAV-FIS SCS. Pursuant to this agreement and appointment Active Ownership Corporation S.à r.l will exercise the voting rights with respect to shares held by Active Ownership Fund SICAV-FIS SCS.
  • Active Ownership Corporation S.à r.l. is an alternative investment fund manager, which can exercise the voting rights at its discretion in the absence of specific instructions.
  • The notification of Active Ownership Corporation S.à r.l. can be viewed via this .

Notification AOC Pharma S.à r.l.

  • On 15 December 2022, Fagron received a notification that the shareholding of AOC Pharma S.à r.l. crossed the disclosure threshold of 5% on 12 December 2022 as the result of the acquisition of voting securities or voting rights.
  • The notification is made by a ‘parent undertaking or a controlling person’.
  • On 12 December 2022, AOC Pharma S.à r.l. held a total of 6,377,392 voting rights.
  • Based on the denominator of 72,992,654 (total number of voting rights), AOC Pharma S.à r.l. held 8.74% of the total number of voting rights on 12 December 2022.
  • AOC Pharma S.à r.l. is controlled by Active Ownership Fund SICAV-FIS SCS. Active Ownership Capital S.à r.l. is the general partner of Active Ownership Fund SICAV-FIS SCS. On 1 October 2019, an agreement was concluded by Active Ownership Fund SICAV-FIS SCS regarding the appointment of Active Ownership Corporation S.à r.l. as AIFM (alternative investment fund manager) for Active Ownership Fund SICAV-FIS SCS. Pursuant to this agreement and appointment Active Ownership Corporation S.à r.l will exercise the voting rights with respect to shares held by Active Ownership Fund SICAV-FIS SCS. Active Ownership Corporation S.à r.l. and Active Ownership Capital S.à r.l. are both jointly controlled by two shareholders, Active Ownership Advisors GmbH and Active Ownership Investments Ltd. Active Ownership Advisors GmbH is controlled by Florian Schuhbauer. Active Ownership Investments Ltd. is controlled by Active Ownership LP, which is controlled by Active Ownership Management Ltd, which is controlled by Klaus Röhrig.
  • The notification of Active Ownership Corporation S.à r.l. can be viewed via this .

Further information

Karen Berg

Global Investor Relations Manager

Tel. 99

About Fagron

Fagron is a leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in 35 countries around the world.

Belgian company Fagron NV has its registered office in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed by the Dutch company Fagron BV, which is headquartered in Rotterdam.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

Please open the link below for the press release:



EN
19/12/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Fagron SA

 PRESS RELEASE

Fagron publishes its Annual Report 2025

Fagron publishes its Annual Report 2025 Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 March 2026 7AM CET Fagron publishes its Annual Report 2025 Fagron, the leading global player in pharmaceutical compounding, today publishes its Annual Report 2025, further to its earlier announcement of Fagron's annual financial results for the financial year 2025 on February 12, 2026. The Annual Report is available on Fagron's in both Dutch (official version, including the ESEF-tagged version) and English. It comprises the annual financial report relating to the consolidated f...

 PRESS RELEASE

Fagron publiceert haar Jaarverslag 2025

Fagron publiceert haar Jaarverslag 2025 Gereglementeerde informatieNazareth (België)/Rotterdam (Nederland), 6 maart 2026 – 7:00 CET Fagron publiceert haar Jaarverslag 2025 Fagron, de toonaangevende wereldwijde speler in farmaceutische bereidingen, publiceert vandaag haar Jaarverslag 2025, volgend op de eerdere bekendmaking van Fagron's jaarlijkse financiële resultaten over het boekjaar 2025 op 12 februari 2026.  Het Jaarverslag is beschikbaar op de van Fagron in zowel het Nederlands (officiële versie, inclusief ESEF-getagde versie) als in het Engels. Het Jaarverslag omvat het financieel...

 PRESS RELEASE

Fagron completes acquisition of Vepakum

Fagron completes acquisition of Vepakum Regulated information – inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 3 March 2026 – 7:00AM Fagron completes acquisition of Vepakum Fagron, the leading global player in pharmaceutical compounding, announces the successful completion of its acquisition of Vepakum in Latin America. The transaction, announced in December 2025, was finalized following regulatory clearance from CADE in early February 2026. Vepakum operates two facilities in São Paulo, Brazil, and specializes in high-quality pharmaceutical packaging solutions. The ac...

 PRESS RELEASE

Fagron voltooit overname van Vepakum

Fagron voltooit overname van Vepakum Gereglementeerde informatie - voorwetenschapNazareth (België)/Rotterdam (Nederland), 3 maart 2026 – 7:00 Fagron voltooit overname van Vepakum Fagron, de toonaangevende wereldwijde speler in farmaceutische bereidingen, maakt bekend dat de overname van Vepakum in Latijns-Amerika succesvol is afgerond. De transactie, die in december 2025 werd aangekondigd, kon worden voltooid nadat CADE, de Braziliaanse mededingingsautoriteit, in februari 2026 goedkeuring verleende. Vepakum beschikt over twee productiefaciliteiten in São Paulo, Brazilië, en is gespecial...

 PRESS RELEASE

Disclosure of a transparency notification from AOC Pharma S.à r.l.

Disclosure of a transparency notification from AOC Pharma S.à r.l. Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 27 02 2026 – 6PM CET Disclosure of a transparency notification from AOC Pharma S.à r.l. Pursuant to the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in listed companies, Fagron received a transparency notification from AOC Pharma S.à r.l., dated 24 February 2026. Notification from AOC Pharma S.à r.l. On 24 February 2026, Fagron received a transparency notification from AOC Pharma S.à r.l., informing the Company that its sharehold...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch